Puma Biotechnology
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib | Seeking Alpha
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Releases Updated Corporate Presentation
Medical Affairs eLearning - MSL Society
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Articles with Puma Biotechnology
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology - Crunchbase Company Profile & Funding
